Inhibitex Shares Popped: What You Need to Know (INHX.DL)

Inhibitex Shares Popped: What You Need to Know

Watch stocks you care about

The single, easiest way to keep track of all the stocks that matter...

Your own personalized stock watchlist!

It's a 100% FREE Motley Fool service...

Click Here Now

Although we don't believe in timing the market or panicking over market movements, we do like to keep an eye on big changes -- just in case they're material to our investing thesis.

What: Shares of anti-infection biotech Inhibitex (Nasdaq: INHX ) seem immune to today's general market malaise, jumping as much as 12.9% in pretty heavy trading.

So what: A Reuters report written in German reminded investors this morning that Swiss pharma giant Roche just might be interested in buying the company for about $2 billion. The gains quickly subsided when everyone realized that Reuters was simply reporting on rumors from earlier this week, which so far haven't led to any actual buyout offers.

Now what: And so the rumor mill reinforces itself like an echo chamber. That said, an Inhibitex buyout isn't out of the question as larger rival Pharmasset (Nasdaq: VRUS ) is getting swallowed by Gilead Sciences (Nasdaq: GILD ) in an $11 billion blockbuster deal. Antivirals are a hot property, and Inhibitex has its fair share of good-looking drug candidates in the pipeline.

Interested in more info about Inhibitex? Click here to add it to My Watchlist.

The Steve Jobs Betrayal
You may already know that in the final year of his life, Jobs revealed a stunning betrayal — and told his biographer, "I will spend my last dying breath... and every penny of Apple's $40 billion in the bank to right this wrong." What was it that made Jobs so irate — and why could it make a few in-the-know investors some major profits over the coming months and years?

Enter your email address below to find out what made Jobs so enraged!

Fool contributor Anders Bylund holds no position in any of the companies mentioned. Motley Fool newsletter services have recommended buying shares of Gilead Sciences. Try any of our Foolish newsletter services free for 30 days. We Fools may not all hold the same opinion, but we all believe that considering a diverse range of insights makes us better investors. Check out Anders' holdings and bio, or follow him on Twitter and Google+. We have a disclosure policy.

Comments from our Foolish Readers

Help us keep this a respectfully Foolish area! This is a place for our readers to discuss, debate, and learn more about the Foolish investing topic you read about above. Help us keep it clean and safe. If you believe a comment is abusive or otherwise violates our Fool's Rules, please report it via the Report this Comment icon found on every comment.